References (55)



Access to Global Disease Innovation

Kevin Outterson

Boston University School of Law

November 15, 2006

The pharmaceutical IP system works well in high-income countries able to afford government subsidies and social insurance. It does not work for the poor in low and middle-income countries. For global diseases (Types I and II), innovation is assured by high-income country markets alone, permitting an accommodation for the poor in low and medium-income countries such as a patent buyout or other access programs which support equitable access without damaging optimal innovation incentives.

Number of Pages in PDF File: 7

Keywords: intellectual property, IP, access, innovation, essential medicines, patent, pharmaceutical

Open PDF in Browser Download This Paper

Date posted: November 16, 2006  

Suggested Citation

Outterson, Kevin, Access to Global Disease Innovation (November 15, 2006). Available at SSRN: https://ssrn.com/abstract=884241 or http://dx.doi.org/10.2139/ssrn.884241

Contact Information

Kevin Outterson (Contact Author)
Boston University School of Law ( email )
765 Commonwealth Avenue
Boston, MA 02215
United States
Feedback to SSRN

Paper statistics
Abstract Views: 1,001
Downloads: 160
Download Rank: 146,955
References:  55